The effect of amycretin, a unimolecular glucagon-like peptide-1 and amylin receptor agonist, on body weight and metabolic dysfunction in mice and ratsResearch in context [PDF]
EBioMedicineSummary: Background: Amycretin is a novel unimolecular glucagon-like peptide-1 (GLP-1) and amylin receptor agonist. This study aimed to determine its role in mitigating diet-induced metabolic disorders, such as obesity, insulin resistance, and fatty ...
Rune Ehrenreich Kuhre +13 more
doaj +4 more sources
Novel Amylin‐Based Therapies for Weight Management in Adults With Overweight or Obesity Without Diabetes: A Network Meta‐Analysis [PDF]
Endocrinology, Diabetes & MetabolismBackground Long‐acting amylin‐based therapies (ABTs) are emerging anti‐obesity agents; we sought to compare their effects on weight and anthropometric outcomes in adults with overweight/obesity without diabetes, evaluate gastrointestinal (GI) safety, and
A. B. M. Kamrul‐Hasan +5 more
doaj +3 more sources
Managing Post-Transplant Diabetes Mellitus after Kidney Transplantation: Challenges and Advances in Treatment [PDF]
PharmaceuticalsKidney transplantation is the most effective treatment for end-stage renal failure but is associated with complications, including post-transplant diabetes mellitus (PTDM).
Grzegorz Rudzki +6 more
doaj +3 more sources
Synthetic target trial emulation and predictive modeling of amylin-pathway therapies for obesity and type 2 diabetes [PDF]
Metabolism OpenIntroduction: Amylin-pathway therapies represent a novel therapeutic class for obesity and type 2 diabetes, however head-to-head comparative data and long-term outcome predictions remain limited.
Faisal A. Al-Harbi +7 more
doaj +2 more sources
Obesity pharmacotherapy reimagined: The era of multi-receptor agonists and next-generation metabolic modulators, perspectives and controversies [PDF]
Metabolism OpenObesity affects over 2 billion adults globally, with projections indicating that nearly two-thirds of adults will be affected by 2050. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have transformed obesity treatment, achieving weight loss ...
Ioannis G. Lempesis, Maria Dalamaga
doaj +2 more sources
Efficacy and safety of incretin co-agonists: Transformative advances in cardiometabolic healthcare. [PDF]
World J CardiolThe ground-breaking development of the incretin agonists by manipulation of the incretin system, including the gut hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), as well as the pancreatic hormone glucagon,
Bhat S +3 more
europepmc +3 more sources
AMYLIN AND AMYLIN ANALOGS – FUTURE THERAPEUTIC STRATEGIES FOR THE TREATMENT OF TYPE 2 DIABETES AND OBESITY [PDF]
Journal of IMABAmylin is a peptide hormone co-synthesized with insulin in pancreatic beta cells at a ratio of 1:100. Notably, amylin has a pronounced tendency to form toxic amyloid fibrils, a characteristic relevant to its pathological role.
Nikolinka Koleva +2 more
doaj +1 more source
Pharmacological Treatment of Obesity: A Review of Current and Future Methods [PDF]
Introduction and objective Obesity poses a significant public health challenge due to its association with an elevated risk of various chronic diseases, including cardiovascular conditions, type 2 diabetes, and overall mortality.
Angelina Lęgas +9 more
core +3 more sources
Futuro en la diabetes: innovaciones terapéuticas y nuevas moléculas
Revista de la Sociedad Argentina de DiabetesExploraremos cuáles son los desafíos más importantes en el tratamiento de la diabetes mellitus (DM). Inicialmente el abordaje terapéutico de la DM fue neutralizar el impacto de las complicaciones crónicas (CC) dado que el diagnóstico era muy tardío ...
León E. Litwak
doaj +1 more source
This article presents a clinical and pharmacological overview of modern incretin receptor agonists used to treat obesity. It examines the evolution of therapeutic approaches, ranging from moderately effective agents (liraglutide) to highly effective long-
S. V. Kizlik +3 more
core +1 more source